Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A concise primer on initial crypto choices, risk awareness, and how to approach your first investment with clarity.
19,614 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Wine stocks rallied on optimism around premium wine demand and stronger consumer spending. Analysts say premiumizatio...
Chevron's CEO warns that jet fuel shortages may push aviation costs higher as carriers trim schedules and consumers f...
HIMU sits vulnerable double risk as slower growth weighs on credits and persistent yields pressure long-duration muni...
As AI reshapes every industry, a few standout names sit beneath the radar. This guide flags the best stocks wall stre...
As InMode lays out its 2026 plan, investors want clarity on growth engines, margins, and execution. This article brea...
Netflix and Meta are trading lower from recent highs, but their risk profiles differ. This piece weighs which merit a...
Looking ahead at geron (gern) 2026 earnings, this guide breaks down the catalysts, cash runway, and risks shaping the...
Spirit Airlines halted operations in the early hours of May 2, 2026, triggering a market storm. Investors and analyst...
ServiceNow's stock is down this year, but CEO Bill McDermott argues AI will accelerate growth, not derail it, outlini...
Looking ahead to 2026, investors want a clear view of how Global Partners will navigate energy markets, margins, and ...
Bank of America economists say the Fed is unlikely to cut rates until 2027, a forecast that could influence mortgages...